

## Prostate cancer drug shows promise against **COVID**

August 18 2023 A Human pluripotent Alveoli stem cells SARS-CoV-2 Fix, Stain Alveolospheres Drug treatment Monolayer Analysis of alpha strain alveoli type II infectivity infection cells (iAEC2 cell) and viability В D С Bliss synergy score: 14.516 -40 -30 30 Inhibition of SARS-CoV-2 infection Viability 56.99 86.94 82.92 83.59 88.73 97.83 100.00 300 93.44 124.35 114.51 129.68 104.44 118.83 106.49 300 30 -20 -10 -0 --10 --20 --30 --40 -300 91.37 113.52 122 49 100 45.09 43.77 57.88 55.17 52.51 88.21 99.06 100 92 50 105 26 113 44 117 08 (MU) Remdesivir (nM) Remdesivir 101.20 102.79 92.72 109.47 97.41 134.10 120.49 74.19 30 37.43 39.69 40.22 64.38 96.3 30 32.64 10 107.50 121.99 131.75 109.71 109.68 112.65 117.0 10 14.53 19.55 25.93 25.47 63.42 11.94 95.70 121.12 116,73 128,47 148.89 97.83 0 0.00 6.01 6.94 4.58 10.57 56.08 82.77 1000 3000 side (nM) 0 100.00 132.56 300 1000 3000 3000 100 10000 300 1000 30 100 10000 300 Proxalutamide (nM) 100 Proxalutamide (nM) Е F G Bliss synergy score: 11.685 -30 30 Inhibition of SARS-CoV-2 infection Viability 66.23 70.50 79.06 106.75 103.63 101.60 98.53 300 56.99 73.50 92.28 300 93.44 99.96 100 45.09 63.56 71.99 83.04 86.73 94.98 100 92.50 105.09 90.65 91.27 86.04 88.77 Remdesivir (nM) Remdesivir (nM) 30 20 10 0 30 32.64 64.21 69.54 79.51 85.20 97.75 30 101.20 106.26 108.09 95.80 95.52 100.91 10 11.94 44.63 55.47 65.48 85.39 95.91 10 136.12 108.35 101.32 112.93 103.38 107.50 -20-149.88 108.82 0 0.00 1 49 30 45 62 57 79.61 97.95 0 100.00 97.32 90.03 93.52 100 Enzalutamide (nM) u 100 300 1000 Enzalutamide (nM) 100 300 1000 3000 0 30 0 3000 30 Enzalutamide (nM)

Proxalutamide and remdesivir combination exerts strong synergistic effect in

30



blocking SARS- CoV- 2 infection in iAEC2. (A) Schematic illustration of the study design of the SARS-CoV-2 bioassay on iAEC2 cells. (B) Combination matrix of proxalutamide and remdesivir in inhibition of SARS-CoV-2 alpha strain infection. (C) Bliss synergy score of proxalutamide and remdesivir against SARS- CoV-2 alpha strain infection. (D) Combination matrix of cell viability on proxalutamide and remdesivir. (E) Combination matrix of enzalutamide and remdesivir in inhibition of SARS- CoV-2 alpha strain infection. (F) Bliss synergy score of enzalutamide and remdesivir against SARS- CoV-2 alpha strain infection. (F) Bliss synergy score of enzalutamide and remdesivir against SARS- CoV-2 alpha strain infection. (G) Combination matrix of cell viability on enzalutamide and remdesivir. Credit: *Proceedings of the National Academy of Sciences* (2023). DOI: 10.1073/pnas.2221809120

At the outset of the COVID pandemic, men appeared to suffer higher rates of severe illness and death, leading researchers to suspect a link between androgen receptors—which bind to hormones like testosterone—and SARS-CoV-2 viral infection.

This observation spurred Michigan Medicine researchers to look into a drug in development to treat prostate cancer called proxalutamide, which works by blocking an enzyme called TMPRSS2 (transmembrane protease, serine 2) that is regulated by <u>androgen receptors</u>, as a potential therapeutic for COVID.

"We were already studying TMPRSS2 as part of the key gene driver of over 50 percent of prostate cancer, so it made sense to look at it as TMPRSS2 is an important host factor for SARS-CoV2 to enter cells in the lung," said Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and the S.P. Hicks Endowed Professor of Pathology.

Chinnaiyan, co-principal investigator Jonathan Sexton, Ph.D., assistant professor of Internal Medicine at the University of Michigan Medical



School and Assistant professor of medicinal chemistry in the College of Pharmacy and their team recently published their study in *PNAS*.

The team added proxalutamide to cells infected with SARS-Co-V2 to monitor its ability to block viral entry.

The compound works by binding to androgen receptors, inhibiting levels of TMPRSS2 and ACE2, and blocking infection.

What's more, proxalutamide worked better than other prostate cancer drugs against multiple variants of SARS-CoV2 due to its ability to break down the androgen receptor.

Additionally, proxalutamide, when combined with FDA-approved COVID drug remdesivir, blocked infection by 100%.

"This discovery underscores the utility of testing existing drugs for <u>new</u> <u>applications</u> that can be rapidly evaluated in humans to shorten the timeline from discovery to clinical evaluation," said Sexton, who is also director of the U-M Center for Drug Repurposing.

Buoyed by their in vitro results, the team looked to see whether the compound could stop the so-called cytokine storm, or severe inflammatory response, caused by SARS-CoV-2 infection.

Using a <u>mouse model</u>, they demonstrated that the drug reduced inflammation and <u>cell death</u> in the lungs of mice and reduced mortality.

Said Chinnaiyan, "The thought is proxalutamide could work as a combined therapy with remdesivir, hitting the virus from multiple angles, much as combination therapy works so well for HIV infection."

The drug is currently in phase 3 <u>clinical trials</u> for <u>prostate cancer</u> and



early clinical trials for COVID.

**More information:** Yuanyuan Qiao et al, Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response, *Proceedings of the National Academy of Sciences* (2023). DOI: 10.1073/pnas.2221809120

Provided by University of Michigan

Citation: Prostate cancer drug shows promise against COVID (2023, August 18) retrieved 28 April 2024 from <u>https://medicalxpress.com/news/2023-08-prostate-cancer-drug-covid.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.